Carmell Stock Price, News & Analysis

Carmell Corporation (Nasdaq: CTCX) has operated as a bio-aesthetics company focused on skin and hair health. According to company disclosures, it utilizes a proprietary technology platform known as the Carmell Secretome™, which consists of a cocktail of growth factors, proteins, peptides and bio-lipids extracted from allogeneic human platelets sourced from U.S. Food and Drug Administration-approved tissue banks. The company states that this technology has been extensively tested over multiple years and is designed to support regenerative applications in aesthetics.

On March 10, 2025, the company announced a corporate rebranding and name change from Carmell Corporation to Longevity Health Holdings, Inc. As part of this change, the company reported that its common stock and redeemable warrants would begin trading under the symbols XAGE and XAGEW, respectively, at the open of trading on that date. The rebranding was described as an effort to better align the company’s market and investor-facing identity with its business focus on longevity and healthy aging.

The company has described its business focus as centered on regenerative bio-aesthetics, with an emphasis on skin and hair health. Its Carmell Secretome™ technology is positioned as a scientific advancement in this area. Company communications explain that the Secretome is formulated into topical products using proprietary delivery systems intended to handle both lipophilic and hydrophilic ingredients while avoiding what it calls the “Foul Fourteen™,” a group of excipients it characterizes as potentially harmful and commonly used by other cosmetic brands to impart texture, stability and other physicochemical attributes. Carmell’s formulations are described as non-comedogenic and free of mineral and vegetable oils.

In addition to its internal technology platform, the company has pursued growth through transactions. In January 2025, Carmell announced the closing of an acquisition of the skin and hair care business of Elevai Skincare, Inc., described as a leader in physician-dispensed exosome-based skin and hair care products. The acquired assets included a product portfolio with reported prior-year revenue, a commercial and product development team, finished and work-in-process inventory, and accounts receivable. The company indicated that this acquisition expanded its bio-aesthetic product portfolio, broadened its commercial footprint and was expected to improve cash flow.

Following the Elevai transaction, the company reported that sales across Carmell and Elevai product lines grew on average over the first two months of 2025 compared to the same period in the prior year, while Elevai’s burn rate was reduced through savings from cutting redundant overhead expenses. The company also highlighted that Elevai’s stem cell exosome technology added a commercial product pipeline to complement Carmell’s allogeneic PRP Secretome platform.

Earlier, in March 2024, Carmell announced the sale of its wholly owned subsidiary Axolotl Biologix (AxoBio) back to the initial sellers of that business. The company stated that this divestiture enabled its exit from the tissue graft space and allowed a sharper organizational focus on the launch and commercialization of skincare products. It also reported that the transaction reduced debt obligations, lowered cash burn and decreased share count through cancellation of shares associated with the AxoBio business.

The company has repeatedly emphasized that its product development and formulations are intended to meet the technical requirements of professional care providers and retail consumers. It has disclosed work on a line of men’s products and a line of topical haircare products, in addition to broader skincare offerings. Carmell has also referenced the development and testing of multiple skincare products for retail and medspa use, as well as in-house manufacturing and packaging capabilities and a direct-to-consumer channel integrated with finance and logistics systems.

Capital formation has been an important part of the company’s story. Carmell has announced several private placement (PIPE) financings with new and existing investors, involving the issuance of common stock and warrants. These transactions were described as intended to support commercial build-out around its bio-aesthetic product pipeline, product development activities and strategic transactions, including acquisitions such as Elevai. The company has also referenced its inclusion in the Russell Microcap Index, which it associated with a period of growth and a pivot towards skincare.

Leadership changes have also been highlighted. In mid-2024, Carmell announced the appointment of a new Chief Executive Officer, describing this as a step to champion a technological approach to regenerative skincare and haircare and to build a broader beauty and wellness platform. The company has characterized its strategy as involving both organic growth of existing brands and potential acquisitions and strategic partnerships in related segments.

With the transition to the Longevity Health Holdings, Inc. name and the change in trading symbols to XAGE and XAGEW, the historical ticker CTCX primarily represents the company’s period operating as Carmell Corporation. Investors researching CTCX stock are therefore looking at the historical identity and disclosures of a bio-aesthetics company that has since rebranded while maintaining a focus on longevity, healthy aging, and regenerative skin and hair health technologies.

Business focus and technology

Company materials describe Carmell’s core technology as the Carmell Secretome™, derived from allogeneic human platelets. The firm reports that the underlying science has been extensively tested over several years, including a prospective, randomized, multi-center Phase 2 human trial referenced in connection with its aesthetic applications. The technology is presented as exceeding standards set by the aesthetics industry in terms of safety and efficacy.

The company has also described a proprietary microemulsion or micellar nanoparticle formulation platform that enables delivery of both lipophilic and hydrophilic ingredients without relying on the Foul Fourteen™ excipients. Across its product line, Carmell states that its formulations avoid mineral and vegetable oils and are designed not to clog pores.

Strategic transactions and portfolio evolution

The acquisition of Elevai Skincare, Inc.’s skin and hair care business is presented by the company as integrating stem cell exosome technology into the Carmell platform. The acquired business focuses on physician-dispensed, science-backed skin and hair care applications and is intended to serve the physician-dispensed market. Carmell has indicated that this transaction expands its bio-aesthetic product portfolio and commercial capabilities.

Conversely, the sale of Axolotl Biologix marked Carmell’s exit from the tissue graft space. The company linked this move to a strategic pivot towards skincare and haircare products, with an emphasis on launching and scaling its aesthetic product pipeline.

Capital markets and ticker transition

Carmell has used the public equity markets to raise capital through private placements of common stock and warrants. These financings were described as priced relative to the prevailing market price of CTCX and structured to provide additional potential proceeds upon warrant exercise. The company has stated that proceeds are intended to support commercialization, product development and strategic transactions.

With the March 10, 2025 rebranding to Longevity Health Holdings, Inc., the company reported that its securities would trade under the new symbols XAGE and XAGEW. As a result, CTCX functions as the historical ticker associated with the Carmell Corporation name and earlier disclosures. For current trading and corporate information, company communications direct attention to the new symbols.

Investor considerations

For investors and researchers, CTCX provides a record of a microcap bio-aesthetics company that has focused on skin and hair health through platelet-derived Secretome technology and proprietary formulation science, augmented by acquisitions such as Elevai and strategic exits such as the sale of Axolotl Biologix. The subsequent rebranding to Longevity Health Holdings, Inc. and shift to XAGE and XAGEW reflect the company’s stated emphasis on longevity, healthy aging, and growth through both organic development and transactions.